Patents by Inventor Melissa A. Kotterman
Melissa A. Kotterman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240066145Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.Type: ApplicationFiled: August 10, 2023Publication date: February 29, 2024Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. Kirn, Melissa Kotterman, David Schaffer
-
Publication number: 20240067987Abstract: The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant A.AV and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.Type: ApplicationFiled: September 15, 2023Publication date: February 29, 2024Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: Melissa Kotterman, Peter Francis, Melissa Calton, Johnny Gonzales, Roxanne Croze, Christopher Schmitt
-
Publication number: 20240018498Abstract: The present disclosure provides codon optimized nucleotide sequences encoding hum n alpha-galactosidase A, vectors, and host cells comprising codon optimized alpha-galactosidase A sequences, and methods of treating disorders such as Fabry disease comprising administering to the subject a codon optimized sequence encoding human alpha-galactosidase A.Type: ApplicationFiled: September 8, 2023Publication date: January 18, 2024Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. KIRN, Melissa KOTTERMAN, Peter FRANCIS, David SCHAFFER, Paul SZYMANSKI, Kevin WHITTLESEY
-
Patent number: 11840704Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of muscle cells as compared to the infectivity of the muscle cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more muscle cells for the treatment of muscle disorders and diseases.Type: GrantFiled: December 21, 2022Date of Patent: December 12, 2023Assignee: 4D Molecular Therapeutics Inc.Inventors: David H. Kirn, Melissa Kotterman, David Schaffer
-
Patent number: 11807868Abstract: The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant AAV and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.Type: GrantFiled: October 6, 2022Date of Patent: November 7, 2023Assignee: 4D Molecular Therapeutics Inc.Inventors: Melissa Kotterman, Peter Francis, Melissa Calton, Johnny Gonzales, Roxanne Croze, Christopher Schmitt
-
Patent number: 11802278Abstract: The present disclosure provides codon optimized nucleotide sequences encoding human alpha-galactosidase A, vectors, and host cells comprising codon optimized alpha-galactosidase A sequences, and methods of treating disorders such as Fabry disease comprising administering to the subject a codon optimized sequence encoding human alpha-galactosidase A.Type: GrantFiled: October 11, 2022Date of Patent: October 31, 2023Inventors: David H. Kirn, Melissa Kotterman, Peter Francis, David Schaffer, Paul Szymanski, Kevin Whittlesey
-
Publication number: 20230340042Abstract: The present disclosure provides codon optimized RPGRorf15 sequences, vectors, and host cells comprising codon optimized RPGRorf15 sequences, and methods of treating retinal disorders such as XLRP comprising administering to the subject a codon optimized RPGRorf15 sequence.Type: ApplicationFiled: August 30, 2021Publication date: October 26, 2023Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. KIRN, Melissa A. KOTTERMAN, David SCHAFFER, Peter FRANCIS
-
Publication number: 20230323311Abstract: The present disclosure provides infectious recombinant adeno-associated virus (rAAV) virions that comprise a variant capsid protein and a heterologous nucleic acid. The present disclosure further provides the variant adeno-associated virus (AAV) capsid proteins (and/or a nucleic acid encoding the variant AAV capsid proteins), which confer to an infectious rAAV virion an increased resistance to human AAV neutralizing antibodies. The present disclosure further provides host cells comprising an infectious rAAV virion and/or a nucleic acid encoding a subject variant AAV capsid protein. The present disclosure further provides methods of delivering a heterologous nucleic acid to a target cell where the target cell is contacted with a subject infectious rAAV virion. The present disclosure further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.Type: ApplicationFiled: March 15, 2023Publication date: October 12, 2023Inventors: David V. Schaffer, Melissa A. Kotterman, Bum-Yeol Hwang, James T. Koerber
-
Patent number: 11766487Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.Type: GrantFiled: December 21, 2022Date of Patent: September 26, 2023Assignee: 4D Molecular Therapeutics Inc.Inventors: David H. Kirn, Melissa Kotterman, David Schaffer
-
Patent number: 11766489Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.Type: GrantFiled: November 26, 2018Date of Patent: September 26, 2023Assignee: 4D Molecular Therapeutics, Inc.Inventors: David H. Kirn, Melissa Kotterman, David Schaffer, Paul Szymanski, Peter Francis
-
Publication number: 20230279435Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of muscle cells as compared to the infectivity of the muscle cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more muscle cells for the treatment of muscle disorders and diseases.Type: ApplicationFiled: December 21, 2022Publication date: September 7, 2023Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. Kirn, Melissa Kotterman, David Schaffer
-
Publication number: 20230257772Abstract: The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant AAV and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.Type: ApplicationFiled: October 6, 2022Publication date: August 17, 2023Applicant: 4D Molecular Therapeutics Inc.Inventors: Melissa Kotterman, Peter Francis, Melissa Calton, Johnny Gonzales, Roxanne Croze, Christopher Schmitt
-
Publication number: 20230211013Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.Type: ApplicationFiled: December 21, 2022Publication date: July 6, 2023Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. Kirn, Melissa Kotterman, David Schaffer
-
Publication number: 20230190964Abstract: The present disclosure provides codon optimized nucleotide sequences encoding human alpha-galactosidase A, vectors, and host cells comprising codon optimized alpha-galactosidase A sequences, and methods of treating disorders such as Fabry disease comprising administering to the subject a codon optimized sequence encoding human alpha-galactosidase A.Type: ApplicationFiled: October 11, 2022Publication date: June 22, 2023Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. Kirn, Melissa Kotterman, Peter Francis, David Schaffer, Paul Szymanski, Kevin Whittlesey
-
Publication number: 20230158172Abstract: The present disclosure provides codon optimized nucleotide sequences encoding human REP1, vectors, and host cells comprising codon optimized REP1 sequences, and methods of treating retinal disorders such as choroideremia comprising administering to the subject a codon optimized sequence encoding human REP1.Type: ApplicationFiled: November 4, 2022Publication date: May 25, 2023Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. Kirn, Melissa A. Kotterman, Peter Francis
-
Patent number: 11634691Abstract: The present disclosure provides infectious recombinant adeno-associated virus (rAAV) virions that comprise a variant capsid protein and a heterologous nucleic acid. The present disclosure further provides the variant adeno-associated virus (AAV) capsid proteins (and/or a nucleic acid encoding the variant AAV capsid proteins), which confer to an infectious rAAV virion an increased resistance to human AAV neutralizing antibodies. The present disclosure further provides host cells comprising an infectious rAAV virion and/or a nucleic acid encoding a subject variant AAV capsid protein. The present disclosure further provides methods of delivering a heterologous nucleic acid to a target cell where the target cell is contacted with a subject infectious rAAV virion. The present disclosure further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.Type: GrantFiled: April 20, 2022Date of Patent: April 25, 2023Assignee: The Regents of the University of CaliforniaInventors: David V. Schaffer, Melissa A. Kotterman, Bum-Yeol Hwang, James T. Koerber
-
Patent number: 11613766Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of muscle cells as compared to the infectivity of the muscle cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more muscle cells for the treatment of muscle disorders and diseases.Type: GrantFiled: April 12, 2022Date of Patent: March 28, 2023Assignee: 4 MOLECULAR THERAPEUTICS INC.Inventors: David H. Kirn, Melissa Kotterman, David Schaffer
-
Patent number: 11576983Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more ceils of the retina for the treatment of retinal disorders and diseases.Type: GrantFiled: May 17, 2022Date of Patent: February 14, 2023Assignee: 4D Molecular Therapeutics Inc.Inventors: David H. Kirn, Melissa Kotterman, David Schaffer
-
Publication number: 20230001018Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more ceils of the retina for the treatment of retinal disorders and diseases.Type: ApplicationFiled: May 17, 2022Publication date: January 5, 2023Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. KIRN, Melissa KOTTERMAN, David SCHAFFER
-
Publication number: 20230002740Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus (OVV) comprising one of more of a) a nucleotide sequence encoding a variant A33 polypeptide, b) a nucleotide sequence encoding a variant A34 polypeptide, and c) a nucleotide sequence encoding a variant B5 polypeptide, wherein the variant A33, variant A34, and variant B5 polypeptides comprise one or more amino acid substitutions that provide for enhanced virus spreading or enhanced EEV production as compared with a virus encoding a corresponding wild-type A33, A 34, and B5 polypeptide. The present disclosure also provides compositions comprising the OVV and use of the OVV or the composition for inducing oncolysis in an individual having a tumor.Type: ApplicationFiled: December 9, 2020Publication date: January 5, 2023Inventors: David H. Kirn, Liliana Maruri Avidal, Todd Brandon Slaby, Darin Michael Abbadessa, Nathaniel Phillip Gulizia, Melissa A. Kotterman